EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Epigenome-Wide DNA Methylation in Unipolar Depression: Predictive Biomarker of Antidepressant Treatment Response?

Miriam A Schiele, Oscar Crespo Salvador, Jan Lipovsek, Kathrin Schwarte, Pascal Schlosser, Peter Zwanzger, Volker Arolt, Bernhard T Baune, Anna Köttgen, Katharina Domschke iD

International Journal of Neuropsychopharmacology · 01.11.2024 · 27 (11)

DOI: 10.1093/ijnp/pyae045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Neuropsychopharmacology, online erschienen am 05.10.2024. Verfasst von Miriam A Schiele und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Hauptthemen laut MEDLINE: DNA Methylation, Antidepressive Agents, Major Depressive Disorder. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dr. Robert Pfleger Stiftung, German Research Foundation, Germany's Excellence Strategy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite the well-documented efficacy of antidepressant agents for the treatment of major depressive disorder (MDD), initial treatment nonresponse rates are high. Recent years have seen an increase in research into predictive biomarkers toward improving diagnosis and individualized treatment. Among those, epigenetic mechanisms such as DNA methylation constitute promising candidate markers in predicting antidepressant treatment response in MDD. The present study sought to address epigenome-wide DNA methylation as a predictor of antidepressant treatment response in the largest sample to date of patients with MDD.

Methods

Epigenome-wide DNA methylation was analyzed using the Infinium MethylationEPIC BeadChip in peripheral blood of n = 230 Caucasian patients with MDD receiving 6-week antidepressant treatment in a naturalistic in-patient setting as well as in a subsample of n = 107 patients primarily receiving continuous treatment with serotonin reuptake inhibitors or serotonin and norepinephrine reuptake inhibitors. Treatment response was assessed by means of the Hamilton Depression Scale.

Results

No genome-wide significant hits were observed. Suggestive (P < 1E-5) epigenome-wide evidence was discerned for altered DNA methylation at 6 CpG sites (LOC102724467, LOC100506023, RSPO2, SAG, IL16, PRKCI) to predict response to naturalistic antidepressant treatment. In patients treated with serotonin reuptake inhibitors or serotonin and norepinephrine reuptake inhibitors, differential DNA methylation at 11 CpGs, for example, mapping to the TIMP2, VDAC1, or SORL1 genes, was suggestively associated with treatment response.

Conclusions

The present results provide preliminary evidence for altered DNA methylation patterns to be associated with antidepressant treatment response in MDD. Provided significant replication in independent and larger samples, the present findings might in the future aid in clinical decision-making toward more individualized and thus more efficacious treatments of MDD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationAntidepressive AgentsMajor Depressive DisorderHumansFemaleMaleAdultMiddle AgedEpigenomeBiomarkersTreatment OutcomeEpigenesis, GeneticSelective Serotonin Reuptake InhibitorsCpG Islands

Stichwörter der Autor:innen

EWASMDDSSRIdepressionepigeneticmethylome

Substanzen

Antidepressive AgentsBiomarkersSelective Serotonin Reuptake Inhibitors

Autor:innen und Institutionen

  • Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg, Germany.
  • Department of Psychiatry and Psychotherapy, University of Münster, Münster, Germany.
  • Centre for Integrative Biological Signalling Studies (CIBSS), University of Freiburg, Freiburg, Germany.
  • Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University of Munich, Munich, Germany.

ORCID-Profile: Katharina Domschke

Förderung

  • Dr. Robert Pfleger Stiftung
  • German Research Foundation
  • Germany's Excellence Strategy
  • Medical Epigenetics
  • Germany’s Excellence Strategy

Zitieren

APA

Schiele, M. A., Crespo Salvador, O., Lipovsek, J., Schwarte, K., Schlosser, P., Zwanzger, P., Arolt, V., Baune, B. T., Köttgen, A., & Domschke, K. (2024). Epigenome-Wide DNA Methylation in Unipolar Depression: Predictive Biomarker of Antidepressant Treatment Response?. International Journal of Neuropsychopharmacology, 27(11). https://doi.org/10.1093/ijnp/pyae045

Vancouver

Schiele MA, Crespo Salvador O, Lipovsek J, Schwarte K, Schlosser P, Zwanzger P, et al. Epigenome-Wide DNA Methylation in Unipolar Depression: Predictive Biomarker of Antidepressant Treatment Response?. International Journal of Neuropsychopharmacology. 2024;27(11). doi:10.1093/ijnp/pyae045

BibTeX
@article{Schiele2024,
  author = {Schiele, Miriam A and Crespo Salvador, Oscar and Lipovsek, Jan and Schwarte, Kathrin and Schlosser, Pascal and Zwanzger, Peter and Arolt, Volker and Baune, Bernhard T and Köttgen, Anna and Domschke, Katharina},
  title = {Epigenome-Wide DNA Methylation in Unipolar Depression: Predictive Biomarker of Antidepressant Treatment Response?},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2024},
  volume = {27},
  number = {11},
  doi = {10.1093/ijnp/pyae045}
}
Kostenlos starten →